 Fy awr iawn y bydd yw'n ddoch yn ymweliad penderfyniadau, sy'n maen nhw'n ddweud y cyhoeddiad ymlaen, yn ymlaen a'r cap o'i ymweliad ymlaen, o'n ddweud o'r ddweud ymweliad o'u'r ddweud yma'r dda'n ei wneud. O'n ddweud o'ch ddweud o'r ddweud o'r ddweud, oherwydd mae'n werthfyniadau'n gwneud o'r ddweud o'r ddweud, Llywodraeth yr hyffordi i'r company, ynghyd o'r unig iawn i'r unig iawn i'r byd, ond mae'r rheswys bêl iawn i'r bai allan i'r byd, mae'r bai iawn i'r byd. Felly yna ymdweithio ar y cyffredin iawn, mae'r byd, yw'r llei'r llei, mae'r bydd maen nhw yn fawr o'r cyfnod ar y byd, ond mae'n gweithio'r ffant, mae'r cyffredin iawn ar y byd, nid yw rhaid i'r fideo yn rhaid, rhaid i'r ffapr. Ac rwy'n meddwl hynny yw'r cael ei gweld ironan yma wedi gweld ddigon ni wedi gweld unigol i gyfweld. Ac dyna aeth ei hunir ag dim am warehau, cyfgweld yr argyrdd yng nghymru a'r cefnod a'r cyfweld yr argyrrdd. Ac mae angen i'r cyfweld yr acri, cyfweld yr argyrdd yr dyna. Yn mwybodol yw'r cyfweld yr argyrdd yr argyrdd argyrdd yng Nghymru, ydy'r cyffinant meddwl, y meddwl yn gwneud o'r bwysig a'r gwahanol i'r bobl yn gweithasol. Ac mae'n gymaint o'r ffordd rhai o'r bwysigau ar gyfer gwaith. Mae'r bwysig yn ymddangos i gael i'r obsigurau. Er mwyn rhaid i'r bwysig, mae'n gael i gael i'r bwysig ar gael i'r brifasol o'r angarol yma. felly wnaeth gwis gwybod yn ddau g-dinkarol, felly rhaid yn dangos'i ddyn nhw, neu ddych chi realmwch cymdeithas, a fyddwch yn ddau'r ddau'r ddau mewn ddau'r gweithio, a ddysgrif Davy, hefyd, mae gennym ni gael gwyfyrdd, wrth gael gweithio'r ddau'r ddau celfwyr yn ddau gwyfyrdd, felly ddweud gyda'r ddau'r ddau gweithio ar gyfer y pwg gyda'r gweithio ar gyfer y piwrdd yma. Cysgwp chi, dwi'n credu. Well first of all my concern here is in the investor presentation the need to not put white next to yellow because it makes it way too hard to read yeah so it's like concern but moving into this so what do they do? So they've got Helomics which is 2019 acquisition provided a key proprietary technology platform and data pipeline for predictive oncology to be a leader and providing next generation AI and data driven services for pharma and diagnostics companies to accelerate the development of new precision therapies. So again this is the AI side of the company and artificial intelligence is a growing industry in itself and it is being used in many different industries including the you know biopharmaceutical industry as well and arguably it's more effective in this industry because it obviously biopharmaceutical companies are often driven by the research and the data yeah. Then you've got this next one called tubogenesis which focuses on developing an approach to grow tumors in the laboratory that mimics the patient's body this platform along with other proprietary FDA approved important technologies merged from the helomics purchase we will be used to fuel the unique and more clinically accountable data so again they're using these two acquisits so they've got this but they're using helomics to actually feed into this this area and kind of grow each one right so the companies that are under their umbrella so to speak of predictive oncology they're kind of helping each other out in a way and there's all this sort of sharing of resources. Then you've got solubu biotech which is a unique technology platform designed to rapidly optimise pharmaceutical formulations needed to deliver protein based therapeutics and vaccines to the market. Then you've got Skyline Medical which is the new standard in waste fluid management the revolutionary FDA approved streamware systems is an automated direct to drain system so you can see that there's a lot of potential in the areas that they're involved with in this company in terms of there's a lot of different areas here and the all kind of really kind of big addressable markets. Now looking at the opportunity this is the opportunity that this particular company sees particularly with the first one that we mentioned there the use of artificial intelligence is it can be used to improve accuracy predictability and the really important part here is the speed of biopharmaceutical rnd so what's rnd that's research and development if they're able to increase the speeds that has a lot of impact for some of these biopharmaceutical companies because they tend to do research and development over long periods of time and if that can be sped up in any way but still maintain its accuracy and you know efficiency then that is a massive selling point for this particular AI intelligence right what is it doing it's going to reduce time and increase agility of the drug discovery process absolutely increase accuracy of efficacy and safety of drugs and improve diversity of drug portfolio so the discovery market how what is the discovery market for this area so they've got 700 million in 2018 and it's set to grow this discovery market set to go for 2025 to 20 billion this is a massive total addressable market lots of companies in the space but biopharma making multiple deals tends to outsource its contract to research organizations most major biopharma in pursuing AI solutions and obviously they're an AI solution in what they're trying to do there as well revenue operations and opportunities you've got biopharma AI deals with ranging has deals ranging from five million dollars to over one billion dollars so over several years with milestones and royalties typical five to 20 million so you can see here that the potential revenue that could be gained from these opportunities which is obviously good as investors they've also got this this area here that that they're involving is so soluble biotech unique technology platform is designed to rapidly optimise pharmaceutical formulations needed to deliver a protein based therapeutics and vaccines to the market and we had this one here that we've already talked about in terms of tumor genesis and some of the investment highlights here so it says that it's manufactured a marketer of the steamware system which solves the most important challenges of medical ways fluid disposal in a safe efficient and cost effective manner a product with numerous competitive features and benefits to healthcare professionals and patients as well as a strong economic argument for hospitals and certain outpatient facilities radiology saving $80 to $100 per procedure a hardware disposable business model and a potential of 24 000 per year unit in disposable sales distribution in the place to the US and internationally more than 180 systems sold in the market so they're selling these systems in this particular steamware system streamware system that they're doing okay so they've got the other areas where they're building the revenue as well so there's like a multiple areas of revenue that could be built okay and you can also see just in terms of the company's history 2015 2016 you can see that the sales and revenue growth is growing okay maybe not as fast as it it should be but but i think that it's kind of going to hit um much higher revenue now when they're because they've made these developments on these products okay but also another interesting point is there has been a recent direct offering and this is good for two reasons one number one it actually is a good cash injection into the business 4.4 million direct offering it's a good cash injection into the business okay in terms of the future but in in in addition to that also it does have a short term impact on the price of the stock and you'll see it dip slightly it already has on this recent news on the january 22nd okay and from that i've actually bought some shares i bought it on the dip and um they they actually got this for $1.20 per share 4.1 million registered direct offering so you can see here it's dipped in the pre-market to 1.23 now i've got a feeling that this stock could double fairly quickly i think in the short term this will double okay and i think in the medium to long term it could three to five x i think that it's just got a lot of potential because of the amount of revenue streams potential revenue streams that it has and i do kind of like the ai side of what it's doing there as well so i would start to buy on the dip because i've had that direct offering so it's dipping at the moment 1.23 i actually the the market's just opened i actually established a position around this point and i think that it's going to increase much further than this okay into the future so thanks for watching the video don't forget to leave the video a like and subscribe to the channel if you knew we cover the latest penny stocks and the hottest penny stocks and also growth stocks and other stuff so do subscribe to the channel if you knew we're trying to reach 10 000 subscribers as fast as we can and be sure to leave a like on the video and i'll see everybody in the next one